Pacira biosciences, inc. (PCRX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Collaborative licensing and milestone revenue

0

3,000

387

3,426

1,426

1,287

972

18,390

5,074

3,217

4,638

Total revenues

421,026

337,277

286,630

276,371

248,997

197,668

85,551

39,084

15,689

14,562

15,006

Operating expenses:
Cost of goods sold

106,712

86,845

87,915

110,104

71,837

77,440

54,772

32,139

16,739

12,276

12,301

Research and development

72,119

55,688

57,290

45,678

28,662

18,731

21,560

9,937

14,873

18,628

26,233

Selling, general and administrative

200,782

177,265

161,494

152,613

139,043

106,662

62,508

46,306

20,159

6,367

5,020

Amortization of acquired intangible assets

5,700

0

0

-

-

-

-

-

-

-

-

Acquisition-related charges, product discontinuation and other

25,230

1,564

4,868

0

0

-

-

-

-

-

-

Impairment of long-lived assets

-

-

-

-

-

-

-

-

3,019

-

-

Total operating expenses

410,546

321,362

311,567

308,395

239,542

202,833

138,840

88,382

54,790

37,271

43,554

Income from operations

10,480

15,915

-24,937

-32,024

9,455

-5,165

-53,289

-49,298

-39,101

-22,709

-28,548

Other (expense) income:
Interest income

7,376

6,497

4,078

1,323

678

382

259

275

255

146

77

Interest expense

23,628

21,949

18,047

7,061

7,725

8,278

7,253

1,807

4,780

3,959

1,723

Loss on early extinguishment of debt

0

-

-3,732

0

-52

-

-3,398

-1,062

0

-184

-

Royalty interest obligation

-

-

-

-

71

323

623

278

-227

930

1,880

Other, net

-4,976

-888

167

-82

-165

-159

-47

-111

71

487

367

Total other expense, net

-21,228

-16,340

-17,534

-5,820

-7,335

-8,378

-11,062

-2,983

-4,227

-4,440

-3,159

Income (loss) before income taxes

-10,748

-425

-42,471

-37,844

2,120

-13,543

-64,351

-52,281

-43,328

-

-

Income tax expense

268

46

140

105

264

173

-442

0

0

-

-

Net income (loss)

-11,016

-471

-42,611

-37,949

1,856

-13,716

-63,909

-52,281

-43,328

-27,149

-31,707

Net income (loss) per share:
Basic and diluted net income (loss) per common share (in USD per share)

-0.27

-0.01

-1.07

-1.02

-

-

-

-1.72

-2.64

-47.29

-55.32

Basic net income (loss) per common share (in USD per share)

-

-

-

-

0.05

-0.39

-1.93

-

-

-

-

Diluted net income (loss per common share (in USD per share)

-

-

-

-

0.04

-0.39

-1.93

-

-

-

-

Weighted average common shares outstanding:
Basic and diluted (in shares)

41,513

40,911

39,806

37,236

36,540

35,299

33,182

30,332

16,437

574

573

Diluted (in shares)

-

-

-

-

41,301

35,299

33,182

-

-

-

573

Product
Total revenues

418,926

332,427

284,342

270,073

244,487

193,526

81,956

18,191

6,895

7,640

10,368

Royalty
Total revenues

2,100

1,850

1,901

2,872

3,084

2,855

2,623

2,503

3,720

3,705

-